US FDA approves Vanda's antipsychotic pill, shares climb

By Sneha S K and Kunal Das Feb 20 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' drug for the treatment of two serious mental health conditions, the company said on Friday, sending its shares surging 30% in extended trading. The drug, branded as Bysanti, is an antipsychotic pill aimed at treating schizophrenia and acute bipolar I disorder. Bysanti,